Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal composition for treating hepatitis B

A technology of composition and medicine, applied in the field of medicine, can solve the problems that patients cannot be cured

Active Publication Date: 2016-09-21
阿南达
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Clinically, α-interferon and nucleoside drug lamivudine, which have been officially approved by the FDA, can only achieve therapeutic effects to a certain extent, and most patients cannot achieve the purpose of cure. After stopping the treatment, " The "rebound" phenomenon is the most difficult problem for medical workers, so the development of new anti-HBV drugs with high efficiency, low toxicity and no "rebound" poses a challenge to medicinal chemists

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition for treating hepatitis B
  • Medicinal composition for treating hepatitis B
  • Medicinal composition for treating hepatitis B

Examples

Experimental program
Comparison scheme
Effect test

experiment example

[0015] Almost all human viruses can be replicated on in vitro cell culture. So far, all antiviral tests need to be tested in cell culture to detect the direct effect of the drug on the virus. In vitro experiments are repeatable, stable and controllable, suitable for many The isolation and propagation of a variety of viruses has a wide range of applications.

[0016] Target compound:

[0017] Dimethyl sulfoxide; MTT (thiazole blue), Shanghai Jianglai Biotechnology Co., Ltd.; reference drug, lamivudine tablets (3TC); GlaxoSmithKline Pharmaceuticals (Suzhou) Co., Ltd.; cell culture medium DMEM, growth solution , prepared with 10% fetal bovine serum, 380 μg / ml G418, 0.03% glutamine, 100 μg / ml each of penicillin and streptomycin;

[0018] experiment equipment

[0019] ELISA kit for detecting hepatitis B surface antigen HBsAg and hepatitis B core antigen HBeAg; incubator; 24-well plate.

[0020] cell line

[0021] 2.2.15 cell line of Hep G2, Ministry of Education / Ministry of H...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicinal composition for treating hepatitis B. The medicinal composition is made from effective quantity of compounds and chemically and pharmaceutically acceptable carriers. The structure of the compounds is shown as follow. A result of a pharmacological testing comparison between the compounds and positive control lamivudine shows that the compounds have remarkable anti-hepatitis B virus activity, low effective concentration and low cytotoxicity, are remarkably better than the positive control lamivudine and can serve as active ingredients for preparing anti-hepatitis B virus drugs.

Description

technical field [0001] The invention relates to the field of medicine, in particular, the invention relates to a pharmaceutical composition for treating hepatitis B. Background technique [0002] According to relevant statistics, there are about 300 million people in the world who are chronic hepatitis B virus (HBV) carriers, and my country accounts for about half of them. Hepatitis B virus infection has become one of the major diseases affecting human health globally. Since HBV infection can lead to chronic hepatitis, cirrhosis and primary liver cancer, it has become one of the nine major diseases affecting human life. Since the relative risk rate of liver cancer among chronic HBV-infected persons compared with non-carriers is 217, about 2 million people die from liver cirrhosis and liver cancer caused by hepatitis B every year in the world. 250,000 people died from chronic liver disease (cirrhosis and liver cancer) related to hepatitis B. Above-mentioned diseases bring h...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/427A61P1/16A61P31/20
CPCA61K31/427
Inventor 李军
Owner 阿南达
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com